The skeletal dysplasia market is anticipated to grow at a modest growth rate during the forecast period.  Skeletal dysplasia disorders include hundreds of conditions affecting bone and cartilage growth of the body. Skeletal dysplasia can affect both the adults and children equally. Children who are born with skeletal dysplasia disorder have uneven size and shape of their legs, arms, trunk, or skull. Several dysplasia disorders such as Platyspondylic can be lethal. Bone deformities in skeletal dysplasia can be diagnosed with the X-rays, Magnetic Resonance Imaging (MRI) scans, or Computed Tomography (CT). In several cases, ultrasound examination can also aid in diagnosing skeletal dysplasia before the birth of the child.

Factors such as advancements in treatment and diagnosis methods are significantly driving the skeletal dysplasia market. In addition to this, increasing R&D activities for the drug discovery that can be used for the treatment of skeletal dysplasia is also anticipated to increase market growth. However, limited treatment options coupled with the high cost of branded drugs is expected to hamper the skeletal dysplasia market during the forecast period.

Segmental Outlook 

The global skeletal dysplasia market is segmented based on type and treatment. Based on the type, the market is sub-segmented into achondroplasia, thanatophoric dysplasia, hypochondroplasia, and others. Further, based on the treatment, the market is sub-segmented into medications, therapy, and others. The other segment contains surgery that is performed to correct the deformities in skeletal dysplasia disorder patients.

The achondroplasia segment by the type will show considerable growth 

The achondroplasia segment is anticipated to grow with a significant CAGR in the skeletal dysplasia market. Achondroplasia is one of the most common types of skeletal dysplasia that causes dwarfism and it appears to affect males and females in equal numbers. This achondroplasia disorder begins at a very early stage of developing a fetus. According to the Nation Organization for Rare Disorders (NORD), the estimated frequency of achondroplasia has ranged between 1 in 15,000 to 35,000 births. Hence, the high prevalence of achondroplasia is anticipated to significantly drive the growth of achondroplasia segment in the skeletal dysplasia market.

Global Skeletal dysplasia Market Share by Type, 2019 (%)

Regional Outlooks

The global skeletal dysplasia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the major market share in the skeletal dysplasia market during the forecast period. The growth of the skeletal dysplasia market in the region is owing to the surge in R&D initiative for the discovery of effective drugs. Europe is also expected to exhibit a significant market share during the forecast period owing to the high awareness regarding the disease. Moreover, the presence of various organizations working in the field of skeletal dysplasia such as the European Skeletal Dysplasia Network (ESDD) and others will also contribute significantly to the skeletal dysplasia market in the region.

Global Skeletal Dysplasia Market Growth, by Region 2020-2026

Asia-Pacific will augment with the considerable growth rate in the skeletal dysplasia market 

Asia-Pacific is anticipated to have a comparatively small market share and is expected to grow at a considerable growth rate during the forecast period. It is due to the increasing awareness related to the treatment of skeletal dysplasia across the region.  Moreover, the ongoing technological advancements in the R&D sectors, rising medical tourism, and growing number of collaborations between various national and international organizations are also anticipated to contribute to the lucrative growth of the market of the region.

Market Players Outlook

The key players of the skeletal dysplasia market include Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Ipsen Pharma, Merck KGaA, Regeneron Pharmaceuticals Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding to the start-ups, and new product launches to stay competitive in the market. 

Recent Activity

• In January 2020, Regeneron Pharmaceuticals, Inc. announced the encouraging results from LUMINA-1, a 44-patient, Phase 2, double-blind placebo-controlled trial that is evaluating garetosmab (REGN2477) in patients with fibrodysplasia ossificans progressiva (FOP). These results are groundbreaking for the treatment of FOP.
• In April 2019, Ipsen Pharma acquired Clementia Pharmaceuticals, a stage biotech company.  Clementia Pharmaceuticals is engaged in providing innovative new treatments for patients with rare bone disorders and other diseases. Therefore, the acquisition will provide the company with various tools for their rare diseases pipeline with a strong cornerstone asset for multiple indications.
• In December 2019, Invitae Corp. announced an initiative “Discover Dysplasias” with BioMarin Pharmaceutical Inc. to offer genetic testing at no charge to patients who show signs or symptoms of having a skeletal dysplasia. This program will be available to healthcare providers in the US and will offer genetic testing for 109 genes associated with skeletal dysplasia, as well as no-charge genetic counseling to help clinicians, patients, and their families understand the results.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global skeletal dysplasia market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.